Skip to content

Comparison of Peroral Endoscopic Myotomy (POEM) With Laparoscopic Heller Myotomy (LHM) for Treatment of Achalasia

Comparison of Peroral Endoscopic Myotomy (POEM) With Laparoscopic Heller Myotomy (LHM) for Treatment of Achalasia, a Retrospective Multicenter Study

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02018705
Acronym
POEM3
Enrollment
47
Registered
2013-12-23
Start date
2013-08-31
Completion date
2014-12-31
Last updated
2019-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comparison of Long-term Success Rates of POEM With LHM, Comparison of Short- Term Success Rates of POEM With LHM

Keywords

POEM, LHM, Achalasia treatment, LES sphincter myotomy

Brief summary

For the treatment of Achalasia, LHM has been the only surgical therapy. Recently, an endoscopic approach for this therapy has been developed (peroral endoscopic Myotomy POEM). Studies show promising short and mid term results for POEM. At present, POEM is considered a promising new technique with the potential to become a standard achalasia treatment. For this to happen, long-term comparative data with LHM is required. Therefore,the intention for this study is to investigate the short and long-term efficacy of POEM for the treatment of achalasia as it was performed in international centers and compare outcomes with database assessment of LHM.

Detailed description

Achalasia is a neurodegenerative esophageal motility disorder characterized by incomplete lower esophageal sphincter (LES) relaxation, increased LES tone, and aperistalsis of the esophagus. The standard surgical treatment for achalasia is laparoscopic Heller Myotomy (LHM). A recent meta-analysis of 105 studies reporting on 7855 patients demonstrated that laparoscopic Heller myotomy is the most effective and long-lasting therapy for achalasia. Superior to Endoscopic balloon dilatation or Botulinumtoxin injection LHM has a one year therapeutic efficacy in approximately 90% of patients. Recently an endoscopic technique emulating the principles of LHM was developed. This technique of a purely endoscopic myotomy has been demonstrated by Pasricha et al. in animal experiments and Inoue et al. reported the first clinical study. Other pilot studies and a larger international multi-center trial have replicated promising results for POEM. Uncontrolled studies show promising short and mid term results for POEM. At present, POEM is considered a promising new technique with the potential to become a standard achalasia treatment. For this to happen, however, comparative data with LHM is required. Our study group intends to investigate the short and long-term efficacy of POEM for the treatment of achalasia as it was performed in international centers and compare outcomes with database assessment of LHM.

Interventions

None listed

Sponsors

Agaplesion Markus Krankenhaus
CollaboratorUNKNOWN
Johannes Gutenberg University Mainz
CollaboratorOTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CollaboratorOTHER
McGill Faculty of Medicine
CollaboratorUNKNOWN
University Hospital, Zürich
CollaboratorOTHER
Aarhus University Hospital
CollaboratorOTHER
Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients with symptomatic achalasia and pre-op barium swallow, manometry and oesophago-gastro-duodenoscopy which have been consistent with the diagnosis * Age \> 18 years with medical indication for interventional achalasia treatment * Availability of Eckardt score at baseline and 12 months after initial treatment

Exclusion criteria

* Patients with previous surgery of the stomach or esophagus * Patients with known coagulopathy * Previous surgical achalasia treatment * Patients with liver cirrhosis and/or esophageal varices * Active esophagitis * Eosinophilic esophagitis * Barrett's esophagus * Stricture of the esophagus * Malignant or premalignant esophageal lesion * Severe Candida esophagitis * Hiatal hernia \> 1cm * Extensive, tortuous dilatation (\>7cm luminal diameter, S shape) of the esophagus

Design outcomes

Primary

MeasureTime frameDescription
treatment success1 year after treatmenttreatment success is defined as an Eckardt Score \</=3

Secondary

MeasureTime frameDescription
procedure related adverse events3 months after treatmentretrospective data for this timepoint can be used of the interval 2-8 months after the initial procedure
lower esophageal sphincter pressure (LESP)3 months after treatmentretrospective data for this timepoint can be used of the interval 2-8 months after the initial procedure
symptomatic reflux and use of antacid medication3 months after treatmentretrospective data for this timepoint can be used of the interval 2-8 months after the initial procedure

Other

MeasureTime frameDescription
any reported GERD dataprocedure to five years after treatment
procedure related complicationsprocedureany complication during performance of treatment that required conversion to either laparoscopic (POEM) or open surgical treatment
duration of procedureprocedureduration of procedure (minutes)
in-hospital stayprocedurein-hospital stay of patients (days)
length of myotomyprocedurelength of myotomy (centimeters)

Countries

Denmark, Germany, Netherlands, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026